Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Thomas Podsadecki"'
Autor:
Wei Liu, Sandeep Dutta, Thomas Podsadecki, Jens Kort, Bifeng Ding, Neddie Zadeikis, Chih-Wei Lin, Armen Asatryan, Campbell Andrew L, Wang Tianli
Publikováno v:
The Journal of Clinical Pharmacology. 57:1616-1624
Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection. The aim of the present studies was to assess the effect of race and ethnicity (white, Han
Autor:
Walid M. Awni, Haoyu Wang, Akshanth R. Polepally, Rajeev M. Menon, Daniel E. Cohen, Amit Khatri, Sven Mensing, Thomas Podsadecki, Patrick J. Marroum, Balakrishna Hosmane, Mukul Minocha
Publikováno v:
The AAPS Journal. 19:1523-1535
The triple direct-acting antiviral (3-DAA) regimen (two co-formulated tablets of ombitasvir/paritaprevir/ritonavir once daily and one tablet of dasabuvir twice daily) for patients with hepatitis C virus (HCV) genotype 1 infection has been reformulate
Autor:
Walid M. Awni, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Nancy S. Shulman, Barbara DaSilva-Tillmann, Thomas Podsadecki, Rajeev M. Menon
Publikováno v:
Clinical Drug Investigation. 37:647-657
All-oral direct-acting antiviral regimens that include combinations of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin were evaluated in hepatitis C virus-infected patients in phase II/III clinical studies. The objective
Autor:
Walid M. Awni, Amit Khatri, Thomas Podsadecki, Doerthe Eckert, Sven Mensing, Akshanth R. Polepally, Sandeep Dutta, Rajeev M. Menon, Shringi Sharma
Publikováno v:
British Journal of Clinical Pharmacology. 83:527-539
Aim To characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir, and dasabuvir) and adjunctive ribavirin and estimate covariate effects in a broad spectrum of subjects wit
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:6244-6251
The direct-acting antiviral regimen of 25 mg ombitasvir–150 mg paritaprevir–100 mg ritonavir once daily (QD) plus 250 mg dasabuvir twice daily (BID) is approved for the treatment of hepatitis C virus genotype 1 infection, including patients coinf
Autor:
Walid M. Awni, Rajeev M. Menon, Thomas Podsadecki, Cheri E. Klein, Yi-Lin Chiu, Sandeep Dutta
Publikováno v:
British Journal of Clinical Pharmacology. 81:929-940
Aims Paritaprevir is a direct acting antiviral agent for use as part of a multidrug hepatitis C virus infection treatment regimen. To characterize the pharmacokinetics, safety, and tolerability of paritaprevir and determine an optimal dosing regimen
Autor:
Bifeng Ding, Sandeep Dutta, Daniel E. Cohen, Thomas Podsadecki, Jennifer R. King, Walid M. Awni, Rajeev M. Menon
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:855-861
The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase inhibitor), referred to as the 3D regimen, and the combination of ombitasvir-pari
Autor:
Ewa Janczewska, Adrian Streinu-Cercel, Brian Conway, István Tornai, Richard Skoien, David R. Shaw, Alejandro Soza, Mudra Kapoor, Wayne Ghesquiere, Xuan Liu, Thomas Podsadecki, Florin Alexandru Caruntu, Y. Liu, Gregory J. Dore, Danielle Sullivan, Francisco Fuster, Yan Luo, Manuela Curescu, Adriana Motoc, Olav Dalgard, Campbell Andrew L, Victoria Aramă, Brygida Knysz, Włodzimierz Mazur, Joe Sasadeusz, Susan Greenbloom
Publikováno v:
Journal of Hepatology. 64:19-28
Background & AimsTelaprevir plus pegylated interferon/ribavirin (TPV+PegIFN/RBV) remains a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many regions. We conducted two open-label, phase IIIb trials comparing safe
Autor:
Sandeep Dutta, Akshanth R. Polepally, Denise König, Sven Mensing, Walid M. Awni, Amit Khatri, Wei Liu, Thomas Podsadecki, Rajeev M. Menon
Publikováno v:
The AAPS Journal. 18:270-280
Direct-acting antiviral agents (DAAs) are established as the standard of care for chronic hepatitis C virus (HCV) infection. One of the newest additions to the HCV arsenal is an oral three-DAA combination therapy (i.e., the 3D regimen) that does not
Autor:
Akshanth R. Polepally, Rajeev M. Menon, Walid M. Awni, Thomas Podsadecki, Apurvasena Parikh, Barbara Da Silva-Tillmann, Prajakta S. Badri, Lino Rodrigues, Sandeep Dutta, Sven Mensing
Publikováno v:
Antiviral Therapy. 21:707-714
Background The three drug direct-acting antiviral regimen (3D regimen) of ombitasvir, paritaprevir/ritonavir and dasabuvir, with and without ribavirin, was evaluated in one Phase II trial and six Phase III trials in over 2,300 HCV genotype-1-infected